05.08.2023 | ASO Author Reflections
ASO Author Reflections: Liver-Directed Therapies for Intrahepatic Cholangiocarcinoma: Are We Comparing Apples and Oranges?
verfasst von:
Sabran J. Masoud, MD, Kristen E. Rhodin, MD, Austin M. Eckhoff, MD, Michael E. Lidsky, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 11/2023
Einloggen, um Zugang zu erhalten
Excerpt
Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive cancer of the biliary epithelium portending dismal survival despite advancements in surgical technique and increased adoption of adjuvant systemic therapy.
1,2 Moreover, curative resection is not achievable for a majority of patients.
3 In early-stage disease, ablation has been proposed for tumors with suitable anatomy, whereas ablative radiotherapy (RT) and catheter-directed interventions are proposed for those without a suitable anatomy. Prior literature and the authors’ own work show inferior survival after ablation compared with resection for most patients, but suggest convergent outcomes for tumors smaller than 3 cm in size (Kanu et al., in review).
4 In the absence of randomized data on liver-directed therapies for small ICC, this study compared outcomes after resection, ablation, and RT within the National Cancer Database. …